Therapeutic Asset Ratings

18,139 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Prednisone Lung Cancer	Pfizer	P4	B (63)
Prednisone Multiple Sclerosis	Holy Name Medical Center, Inc.	P4	B (63)
Pregabalin Breast Cancer	Jules Bordet Institute	P4	B (63)
Propofol Breast Cancer	University of Rijeka	P4	B (63)
Pyrotinib Breast Cancer	Fudan University	P4	B (63)
Ribociclib Breast Neoplasm	Eli Lilly and Company	P4	B (63)
Ribociclib Neoplasm	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P4	B (63)
Rilpivirine Fatty Liver Disease	Fundacion SEIMC-GESIDA	P4	B (63)
Rivaroxaban Cardiovascular Disorder	China National Center for Cardiovascular Diseases	P4	B (63)
Ropivacaine Developmental Dysplasia Of The Hip	University of California, Los Angeles	P4	B (63)
Rosuvastatin Acute Coronary Syndrome	Nanjing First Hospital, Nanjing Medical University	P4	B (63)
Sacubitril Hypertensive Disorder	Jing Liu	P4	B (63)
Sevoflurane Lung Cancer	Kaohsiung Medical University Chung-Ho Memorial Hospital	P4	B (63)
Sevoflurane Cancer	Hong Kong Children's Hospital	P4	B (63)
Sevoflurane Colorectal Cancer	Uppsala University	P4	B (63)
Simvastatin Traumatic Brain Injury	Assiut University	P4	B (63)
Sitagliptin Lewy Body Dementia	Mayo Clinic	P4	B (63)
Sulfur Hexafluoride Renal Cell Carcinoma	john eisenbrey	P4	B (63)
Tacrolimus Lymphoma	National Cancer Institute (NCI)	P4	B (63)
Tadalafil Obesity Disorder	Philip Kern	P4	B (63)
Tamoxifen Her2-Receptor Negative Breast Cancer	University of Chicago	P4	B (63)
Tenofovir Alafenamide Hepatocellular Carcinoma	Taipei Veterans General Hospital, Taiwan	P4	B (63)
Thiotepa Plasma Cell Myeloma	First Affiliated Hospital Xi'an Jiaotong University	P4	B (63)
Trabectedin Ovarian Cancer	Grupo Español de Investigación en Cáncer de Ovario	P4	B (63)
Ursodeoxycholic Acid Metabolic Dysfunction-Associated Steatotic Liver Disease	Phenomen Pharma	P4	B (63)

Showing 2601 to 2625 of 18,139 assets

PreviousPage 105 of 726Next